ProfileGDS5678 / 1455422_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 93% 92% 92% 85% 88% 88% 84% 92% 94% 92% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.190494
GSM967853U87-EV human glioblastoma xenograft - Control 27.9867293
GSM967854U87-EV human glioblastoma xenograft - Control 37.9879193
GSM967855U87-EV human glioblastoma xenograft - Control 47.7960292
GSM967856U87-EV human glioblastoma xenograft - Control 57.7413592
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1740485
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7373188
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8736288
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1679884
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7302792
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.1052694
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6926992
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6849292
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.838893